Dave Lennon's CEO adventure goes from preclinical to commercial; GSK vet embarks on new Odyssey with Gary Glick
After stepping into the CEO post for the first time about two years ago, taking over the helm of “tissue therapeutics” startup Satellite Bio, Dave Lennon is ready to take on his next challenge in the C-suite.
On Monday, he traded hats from the preclinical Boston startup for the commercial-stage Los Angeles drugmaker Aadi Bioscience. About a year and a half into the launch of its ultra-rare sarcoma drug Fyarro, Aadi has big label expansion plans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.